Literature DB >> 25684021

Interleukin-15-activated natural killer cells kill autologous osteoclasts via LFA-1, DNAM-1 and TRAIL, and inhibit osteoclast-mediated bone erosion in vitro.

Shan Feng1,2, Suzi H Madsen1, Natasja N Viller3, Anita V Neutzsky-Wulff1,4, Carsten Geisler2, Lars Karlsson1, Kalle Söderström1,5.   

Abstract

Osteoclasts reside on bone and are the main bone resorbing cells playing an important role in bone homeostasis, while natural killer (NK) cells are bone-marrow-derived cells known to play a crucial role in immune defence against viral infections. Although mature NK cells traffic through bone marrow as well as to inflammatory sites associated with enhanced bone erosion, including the joints of patients with rheumatoid arthritis, little is known about the impact NK cells may have on mature osteoclasts and bone erosion. We studied the interaction between human NK cells and autologous monocyte-derived osteoclasts from healthy donors in vitro. We show that osteoclasts express numerous ligands for receptors present on activated NK cells. Co-culture experiments revealed that interleukin-15-activated, but not resting, NK cells trigger osteoclast apoptosis in a dose-dependent manner, resulting in drastically decreased bone erosion. Suppression of bone erosion requires contact between NK cells and osteoclasts, but soluble factors also play a minor role. Antibodies masking leucocyte function-associated antigen-1, DNAX accessory molecule-1 or tumour necrosis factor-related apoptosis-inducing ligand enhance osteoclast survival when co-cultured with activated NK cells and restore the capacity of osteoclasts to erode bone. These results suggest that interleukin-15-activated NK cells may directly affect bone erosion under physiological and pathological conditions.
© 2015 Novo Nordisk A/S.

Entities:  

Keywords:  DNAX accessory molecule-1; leucocyte function-associated antigen-1; natural killer cytotoxicity; osteoclast; tumour necrosis factor-related apoptosis-inducing ligand

Mesh:

Substances:

Year:  2015        PMID: 25684021      PMCID: PMC4479536          DOI: 10.1111/imm.12449

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  48 in total

Review 1.  Inhibitory and activating receptors involved in immune surveillance by human NK and myeloid cells.

Authors:  M Colonna; H Nakajima; M Cella
Journal:  J Leukoc Biol       Date:  1999-11       Impact factor: 4.962

2.  A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2.

Authors:  Y Ogata; A Kukita; T Kukita; M Komine; A Miyahara; S Miyazaki; O Kohashi
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

3.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

Authors:  S Kotake; N Udagawa; N Takahashi; K Matsuzaki; K Itoh; S Ishiyama; S Saito; K Inoue; N Kamatani; M T Gillespie; T J Martin; T Suda
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

Review 4.  Cells of the immune system orchestrate changes in bone cell function.

Authors:  Sarah E Wythe; Vicky Nicolaidou; Nicole J Horwood
Journal:  Calcif Tissue Int       Date:  2013-08-03       Impact factor: 4.333

Review 5.  Apoptosis in bone physiology and disease.

Authors:  D E Hughes; B F Boyce
Journal:  Mol Pathol       Date:  1997-06

6.  Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts.

Authors:  Natasja Nielsen; Veronique Pascal; Andreas E R Fasth; Yvonne Sundström; Elisabeth D Galsgaard; David Ahern; Martin Andersen; Bo Baslund; Else M Bartels; Henning Bliddal; Marc Feldmann; Vivianne Malmström; Louise Berg; Pieter Spee; Kalle Söderström
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

7.  Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption.

Authors:  Morten A Karsdal; Kim Henriksen; Mette G Sørensen; Jeppe Gram; Sophie Schaller; Morten H Dziegiel; Anne-Marie Heegaard; Palle Christophersen; Thomas J Martin; Claus Christiansen; Jens Bollerslev
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

8.  Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells.

Authors:  E Jimi; I Nakamura; L T Duong; T Ikebe; N Takahashi; G A Rodan; T Suda
Journal:  Exp Cell Res       Date:  1999-02-25       Impact factor: 3.905

9.  Effect of IL-15 and natural killer cells on osteoclasts and osteoblasts in a mouse coculture.

Authors:  Hiroaki Takeda; Takeshi Kikuchi; Kyoko Soboku; Iichiro Okabe; Hiroki Mizutani; Akio Mitani; Yuichi Ishihara; Toshihide Noguchi
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

10.  Vitamin D receptor in osteoblasts is a negative regulator of bone mass control.

Authors:  Yoko Yamamoto; Tatsuya Yoshizawa; Toru Fukuda; Yuko Shirode-Fukuda; Taiyong Yu; Keisuke Sekine; Takashi Sato; Hirotaka Kawano; Ken-Ichi Aihara; Yuko Nakamichi; Tomoyuki Watanabe; Masayo Shindo; Kazuki Inoue; Erina Inoue; Naoya Tsuji; Maiko Hoshino; Gerard Karsenty; Daniel Metzger; Pierre Chambon; Shigeaki Kato; Yuuki Imai
Journal:  Endocrinology       Date:  2013-02-06       Impact factor: 4.736

View more
  15 in total

1.  IL15RA is required for osteoblast function and bone mineralization.

Authors:  Emanuele Loro; Girish Ramaswamy; Abhishek Chandra; Wei-Ju Tseng; Manoj K Mishra; Eileen M Shore; Tejvir S Khurana
Journal:  Bone       Date:  2017-06-06       Impact factor: 4.398

Review 2.  [Research progress on mechanism of myokines regulating bone tissue cells].

Authors:  Hongcheng Peng; Zhen Hua; Huilin Yang; Jianwei Wang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2021-07-15

Review 3.  The role of NK cells in rheumatoid arthritis.

Authors:  Anwar Fathollahi; Leila Nejatbakhsh Samimi; Maassoumeh Akhlaghi; Ahmadreza Jamshidi; Mahdi Mahmoudi; Elham Farhadi
Journal:  Inflamm Res       Date:  2021-09-27       Impact factor: 4.575

4.  Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells.

Authors:  Jonas R M Van Audenaerde; Jorrit De Waele; Elly Marcq; Jinthe Van Loenhout; Eva Lion; Johan M J Van den Bergh; Ralf Jesenofsky; Atsushi Masamune; Geert Roeyen; Patrick Pauwels; Filip Lardon; Marc Peeters; Evelien L J Smits
Journal:  Oncotarget       Date:  2017-05-25

Review 5.  The Role of the Molecular Clock in Skeletal Muscle and What It Is Teaching Us About Muscle-Bone Crosstalk.

Authors:  Lance A Riley; Karyn A Esser
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

6.  Antibiotics with Interleukin-15 Inhibition Reduce Joint Inflammation and Bone Erosions but Not Cartilage Destruction in Staphylococcus aureus-Induced Arthritis.

Authors:  Berglind Bergmann; Pernilla Jirholt; Petra Henning; Catharina Lindholm; Claes Ohlsson; Iain B McInnes; Ulf H Lerner; Inger Gjertsson
Journal:  Infect Immun       Date:  2018-04-23       Impact factor: 3.441

Review 7.  Updates on Osteoimmunology: What's New on the Cross-Talk Between Bone and Immune System.

Authors:  Marco Ponzetti; Nadia Rucci
Journal:  Front Endocrinol (Lausanne)       Date:  2019-04-18       Impact factor: 5.555

Review 8.  The potential risks of C-C chemokine receptor 5-edited babies in bone development.

Authors:  Yong Xie; Shaohua Zhan; Wei Ge; Peifu Tang
Journal:  Bone Res       Date:  2019-01-29       Impact factor: 13.567

9.  IL-15 deficiency alleviates steroid-induced osteonecrosis of the femoral head by impact osteoclasts via RANKL-RANK-OPG system.

Authors:  Zubin Zhou; Yiwei Lin; Chenhao Pan; Nan Wang; Lihui Zhou; Haojie Shan; Youshui Gao; Xiaowei Yu
Journal:  Immun Ageing       Date:  2020-06-12       Impact factor: 6.400

10.  Potential therapeutic effects of cyanidin-3-O-glucoside on rheumatoid arthritis by relieving inhibition of CD38+ NK cells on Treg cell differentiation.

Authors:  Hongxing Wang; Shutong Li; Guoqing Zhang; Hui Wu; Xiaotian Chang
Journal:  Arthritis Res Ther       Date:  2019-10-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.